Amylyx Pharmaceuticals (AMLX) vs Telix Pharmaceuticals (TLX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Amylyx Pharmaceuticals (AMLX) has outperformed Telix Pharmaceuticals (TLX) over the past year, gaining 103.3% versus a gain of 11.8%. Telix Pharmaceuticals is the larger company by market cap ($3.78 billion vs $3.44 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AMLX | TLX |
|---|---|---|
| Share price | $27.43 | $11.12 |
| Market cap | $3.44B | $3.78B |
| 1-day change | -2.18% | +3.15% |
| YTD return | +127.07% | +48.46% |
| 1-year return | +103.34% | +11.76% |
| P/E ratio (TTM) | — | 111.20 |
| EPS (TTM) | $-1.41 | $0.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | $803.79M |
| Revenue growth (YoY) | -100.00% | +55.61% |
| Net income (latest FY) | $-144.74M | $-7.13M |
| Gross margin | — | 53.05% |
| Operating margin | — | 3.70% |
| Net margin | — | -0.89% |
| 52-week high | $41.14 | $13.11 |
| 52-week low | $10.83 | $6.28 |
| Distance from 52-week high | -33.33% | -15.18% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +54.43% | +83.63% |
| Average volume | 2.33M | 249.35K |
| Shares outstanding | 125.51M | 339.78M |
| Employees | 136 | 1,120 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AMLX has outperformed TLX by 91.6 percentage points over the past year.
- Telix Pharmaceuticals grew revenue faster in its latest fiscal year (+55.61% vs -100.00%).
About Amylyx Pharmaceuticals
AMLX stock →Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism.
Health Care · Biotechnology: Pharmaceutical Preparations · 136 employees
About Telix Pharmaceuticals
TLX stock →Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,120 employees
AMLX vs TLX FAQ
Which is bigger, Amylyx Pharmaceuticals or Telix Pharmaceuticals?
Telix Pharmaceuticals (TLX) is larger, with a market capitalization of $3.78B compared with $3.44B for Amylyx Pharmaceuticals (AMLX).
Which stock has performed better over the past year, AMLX or TLX?
AMLX returned +103.34% over the past 12 months, compared with +11.76% for TLX (price return, excluding dividends). Past performance does not predict future results.
Are Amylyx Pharmaceuticals and Telix Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.